Insulin Degludec (U-100) Prefilled Pens and Repaglinide and Metformin Tablets
Determining the interaction of Insulin Degludec (U-100) Prefilled Pens and Repaglinide and Metformin Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using metFORMIN together with repaglinide can increase the risk of hypoglycemia, or low blood sugar. You may need a dose adjustment or more frequent monitoring of your blood sugar to safely use both medications. Let your doctor know if you experience hypoglycemia during treatment. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.
MANAGEMENT: A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.
- Wiernsperger N, Rapin JR "Metformin-insulin interactions: from organ to cell." Diabetes Metab Rev 11 Suppl (1995): s3-12
- Okada S, Ishii K, Hamada H, Tanokuchi S, Ichiki K, Ota Z "Can alpha-glucosidase inhibitors reduce the insulin dosage administered to patients with non-insulin-dependent diabetes mellitus?" J Int Med Res 23 (1995): 487-91
Generic Name: insulin degludec
Brand name: Tresiba, Tresiba FlexTouch
Synonyms: Insulin degludec, Insulin Degludec
Generic Name: metformin / repaglinide
Brand name: PrandiMet
Synonyms: Metformin and repaglinide, Repaglinide and Metformin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin Degludec (U-100) Prefilled Pens-Repaglinide Tablets
- Insulin Degludec (U-100) Prefilled Pens-Repan
- Insulin Degludec (U-100) Prefilled Pens-Repara Silver Nitrate Applicators
- Insulin Degludec (U-100) Prefilled Pens-Replace
- Insulin Degludec (U-100) Prefilled Pens-Replace Without Iron
- Insulin Degludec (U-100) Prefilled Pens-Replesta
- Repaglinide and Metformin Tablets-Insulin Degludec (U-100) Vials
- Repaglinide and Metformin Tablets-Insulin Degludec (U-200) Prefilled Pens
- Repaglinide and Metformin Tablets-Insulin degludec and liraglutide
- Repaglinide and Metformin Tablets-Insulin degludec and liraglutide Subcutaneous
- Repaglinide and Metformin Tablets-Insulin degludec Subcutaneous
- Repaglinide and Metformin Tablets-Insulin detemir